TITLE

Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open-Label Observational Study

AUTHOR(S)
Imhof, Alexander; Walter, Roland B.; Schaffner, Andreas
PUB. DATE
April 2003
SOURCE
Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, p943
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on amphotericin B deoxycholate (AmB-d) that remains a mainstay of antifungal therapy for immunocompromised patients, despite being associated with therapy-related toxicity. Median duration of AmB-d therapy; Possibility of dose escalation without delay in 28 patients.
ACCESSION #
9631048

 

Related Articles

  • Lipid Formulations of Amphotericins: Are You a Lumper or a Splitter? Wingard, John R. // Clinical Infectious Diseases;10/1/2002, Vol. 35 Issue 7, p891 

    Editorial. Analyzes the wisdom of grouping together lipid formulations of amphotericin as alternatives to conventional amphotericin B for empirical antifungal therapy. Pharmacokinetic differences in the formulations; Difference in mortality rates; Differences in efficacy.

  • Amphotericin B Deoxycholate Administered by Continuous Infusion: Does the Dosage Make a Difference? Hiemenz, John W. // Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, p952 

    Focuses on amphotericin B deoxycholate (AmB-d) which has been the agent of choice for the treatment of patients who are at high risk for or who have documented invasive fungal infections. Decrease in the incidence of drug-related toxicity through the use of continuous infusion of conventional...

  • Lipid-based Antifungal Agents Current Status. Arikan, Sevtap; Rex, John H. // Current Pharmaceutical Design;Mar2001, Vol. 7 Issue 5, p393 

    Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limited number of antifungal agents available and their high rate of toxicity...

  • Candida lusitaniae Infections in the Era of Fluconazole Availability. Hawkins, Jimmy L.; Baddour, Larry M. // Clinical Infectious Diseases;1/15/2003, Vol. 36 Issue 2, pe14 

    Amphotericin B resistance among isolates of Candida lusitaniae has distinguished it among Candida species. Because no comprehensive review has been published recently, we provide a case report and a literature review of C. lusitaniae infection to update and better characterize the illness in the...

  • Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever. Walsh, Thomas J.; Pappas, Peter; Winston, Drew J.; Lazarus, Hillard M.; Petersen, Finn; Raffalli, John; Yanovich, Saul; Stiff, Patrick; Greenberg, Richard; Donowitz, Gerald; Schuster, Mindy; Reboli, Annette; Wingard, John; Arndt, Carola; Reinhardt, John; Hadley, Susan; Finberg, Robert; Laverdière, Michél; Perfect, John; Garber, Gary // New England Journal of Medicine;1/24/2002, Vol. 346 Issue 4, p225 

    Background: Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative. Methods: In a randomized, international,...

  • Empirical Antifungal Therapy – New Options, New Tradeoffs. Marr, Kieren A. // New England Journal of Medicine;1/24/2002, Vol. 346 Issue 4, p278 

    The article focuses on the author's views on an empirical antifungal therapy. The author reports that empirical antifungal therapy is employed for patients with neutropenia, who have persistent fever despite the administration of antibacterial agents. The author refers to a recent study by T.J....

  • An Evaluation of Hepatotoxicity and Nephrotoxicity of Liposomal Amphotericin B (L-AMB). Patel, Gourang P.; Crank, Christopher W.; Leikin, Jerrold B. // Journal of Medical Toxicology;Mar2011, Vol. 7 Issue 1, p12 

    Hepatic and renal functions are important considerations when selecting antifungal therapy. This investigation of liposomal amphotericin B (L-AMB) was conducted to determine the incidence and factors associated with the development of hepatotoxicity and nephrotoxicity. A retrospective chart...

  • Reply. Winston, Drew J.; Schiller, Gary J. // Clinical Infectious Diseases;10/1/2000, Vol. 31 Issue 4, p1118 

    Argues that randomized, double-blind multicenter trials should be standard for the assessment of the comparative efficacy and safety of emerging antifungal agents. Comparison of amphotericin B lipid complex with amphotericin B as empirical antifungal therapy for patients with febrile neutropenia.

  • Antifungal Susceptibility of the Aspergillus Species by Etest and CLSI Reference Methods. Badiee, Parisa; Alborzi, Abdolvahab; Moeini, Mahsa; Haddadi, Pedram; Farshad, Shohreh; Japoni, Aziz; Ziyaeyan, Maziar // Archives of Iranian Medicine (AIM);Jul2012, Vol. 15 Issue 7, p429 

    Background: Because resistance to antifungal drugs is seen in patients, susceptibility testing of these drugs aids in choosing the appropriate drug and respective epidemiology. This study has investigated and compared susceptibility patterns of the Aspergillus species isolated from patients by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics